SHENZHEN, China, June 13, 2025 (GLOBE NEWSWIRE) -- As a leading brand in the global vaping industry, Airis once again redefines industry expectations with the launch of its latest flagship product, the NEO P40000. This revolutionary product integrates an intelligent monitoring system, triple-core ultra-fast vaporization, five-level nicotine adjustment, and 15 authentic flavors, it not only redefines the user experience of disposable e-cigarettes but also leads global users into a new era of “smart, premium, ...

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges ...

VEON Ltd. (NASDAQ: VEON ) is a leading global digital operator, combining traditional telecommunication services, fast-growing fintech and streaming services across 5 key high growth frontier markets. Its market cap is only $3.3bn, and it is significantly lower than its peers like Bharti Airtel of $130bnI am currently working as an investment analyst at a family office. My specialty is identifying high-quality and/or severely mispriced investment ideas. I believe that a great investment idea would "jump" at ...

Pinnacle West (NYSE: PNW ) and Avista Corporation (NYSE: AVA ) are close peers in that they’re both regulated electric utilities operating in the Western U.S., but they have rather different investment profiles. Arizona-based PNW has growthJoseph Jones, professor at The University of Southern Mississippi, has over fifteen years of experience studying the market. He focuses on portfolio construction from a dividend growth investor's perspective. The insights expressed in his research are solely his own; they ...

Quantum computing stocks are still quite hot in the market, although their week-to-week performance can be incredibly volatile. For example, one of the more popular quantum computing plays, Rigetti Computing (RGTI -3.12%), set a new all-time high right at the end of 2024, but plunged 70% just a few weeks into 2025. Now, it's only off around 40% from its all-time high. One of its peers, IonQ (IONQ -2.28%), has also seen extreme volatility, although not quite the same level as Rigetti.Of these two, is one a m ...

Group 1 - The company is reducing its mortgage banking income estimate due to a weak housing market [1] - The expected EPS for the company in 2025 has been revised down to $1.43 from a previous estimate of $1.67 [1]

One of the most popular investment strategies rests on finding businesses that can quickly increase their revenue and earnings. By putting money into these opportunities, investors are hoping they can generate strong portfolio returns.There's one growth stock up 17% in 2025 (as of June 10). That performance trounces the 2% gain of the S&P 500 index (^GSPC 0.38%). But investors might not be familiar with this business, given that it carries a market cap of just $6.8 billion.Maybe now is a good time to take a ...

Group 1 - Danske Bank A/S has notified Netcompany Group A/S regarding their direct and indirect holdings and voting rights in the company [1][2] - As of June 11, 2025, Danske Bank A/S controls 2,587,150 voting rights, which corresponds to 5.45% of the total voting rights in Netcompany [2]

Core Insights - RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to enhance its DNA GPS Pharmacogenetics initiatives aimed at optimizing personalized treatment pathways for retinal and systemic diseases [1][5] - Dr. Langaee brings over 20 years of experience in pharmacogenomics and precision medicine, overseeing genotyping, sequencing data processing, and clinical genetic association studies [2][3] - The company aims to integrate advanced retinal imaging with pharmacogenetics and AI to identify early signs of chronic diseases, thereby improving overall health management and reducing long-term healthcare costs [6][7] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by combining genetic screening, advanced imaging, and therapeutic development [9] - The company's proprietary technologies include High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™, which are designed to prevent blindness and detect physiological changes indicating future ocular and systemic diseases [9] Strategic Goals - The integration of Dr. Langaee's expertise is expected to accelerate the company's efforts in delivering personalized, data-driven solutions for retinal and systemic health [5] - RetinalGenix's approach includes remote monitoring and personalized risk assessments based on genetic profiles, which aims to maximize the effectiveness of preventive strategies [7][8]

Core Insights - Digital Turbine, Inc. is expected to report a quarterly earnings decline to 4 cents per share, down from 12 cents per share in the same period last year [1] - The company projects quarterly revenue of $116.64 million, an increase from $112.22 million a year earlier [1] Recent Performance - On February 5, Digital Turbine reported quarterly earnings of 13 cents per share, exceeding the analyst consensus estimate of a loss of 1 cent [2] - Quarterly revenue was reported at $134.64 million, surpassing the consensus estimate of $123.68 million [2] - Following the earnings report, Digital Turbine shares fell by 4.1% to close at $4.98 [2] Analyst Ratings - B of A Securities analyst downgraded the stock from Neutral to Underperform, reducing the price target from $3.5 to $1 [6] - Macquarie analyst maintained a Neutral rating and lowered the price target from $3 to $2 [6] - Craig-Hallum analyst maintained a Buy rating but cut the price target from $5 to $4 [6]